BioLine Rx (FRA:YP2) Moat Score: 4/10 (As of Jul. 01, 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.48
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Moat Score?

BioLine Rx FRA:YP2 -2.36% 21 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 1,400 Biotechnology companies, BioLine Rx ranks better than 88.79% on this metric.

BioLine Rx has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

BioLine Rx has Narrow Moat: BioLine Rx Ltd has a discernible but modest moat due to its pipeline of proprietary drug candidates and some intellectual property. However, the company faces significant competition in the biotech industry and lacks strong brand strength or regulatory barriers. Its moat is primarily based on its R&D capabilities.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioLine Rx might have Narrow Moat - Discernible but modest moat.

BioLine Rx  (FRA:YP2) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioLine Rx Moat Score Related Terms

FRA:YP2 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, BioLine Rx's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Moat Score distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Moat Score falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
BioLine Rx (FRA:YP2) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioLine Rx ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is BioLine Rx's Moat Score too high?
BioLine Rx's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. BioLine Rx's value of 4 is 100% above this industry median. Based on the distribution chart, BioLine Rx ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #157 out of 1400 companies for Moat Score. This places BioLine Rx in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. BioLine Rx's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLine Rx's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLine Rx's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price